ArticlePloS one2026
Optimisation of metabolic dysfunction-associated steatotic liver disease (MASLD) screening algorithm for resource-poor settings using machine learning.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe European Association for the Study of the Liver (EASL) metabolic dysfunction-associated steatotic liver disease (MASLD) screening algorithm involves two steps: initial screening with FIB-4, followed by referral for vibration-controlled transient elastography (VCTE) in patients likely to have significant fibrosis (SF). However, VCTE is not widely available in resource-limited settings.
aimTo optimise the EASL MASLD screening algorithm for resource-poor settings using machine learning (ML).
methodsWe analysed data from 964 adults aged ≥35 years who underwent VCTE at a tertiary referral centre in Sri Lanka between November 2024 and 2025. Multiple ML models using different methods and variable combinations were trained on 80% of the dataset and tested on the remaining 20%. The best models were selected based on performance and externally validated on data from 430 patients who underwent VCTE before November 2024. Model performance was compared with that of the FIB-4 score using confusion matrices.
resultsA Random Forest model incorporating age, AST, ALT, and platelet count separately, rather than using the FIB-4 score, outperformed in predicting SF. The model using all variables showed the best predictive performance for SF, with an AUC-ROC of 0.808. The variables used in the model, in descending order of feature importance, were AST, platelet count, BMI, diabetes mellitus, ALT, age, hypertension, dyslipidaemia, sex, family history, diabetes complication, hypothyroidism, and smoking. External validation of the all-variable model demonstrated an AUC of 0.795 and predicted SF in 9.0% more patients without increasing negative VCTE referrals compared with using the FIB-4 score as the screening tool in the first step of the MASLD screening algorithm.
conclusionsML-based models were more effective than the FIB-4 score as the first-line screening tool for VCTE referrals, substantially improving the identification of patients with significant fibrosis in this South Asian cohort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.